<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817011</url>
  </required_header>
  <id_info>
    <org_study_id>2006-03-012</org_study_id>
    <nct_id>NCT00817011</nct_id>
  </id_info>
  <brief_title>Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness</brief_title>
  <acronym>PG</acronym>
  <official_title>Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to predict antidepressant response in advance using
      pharmacogenomics and peripheral biological markers in depressed patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The difficulties to treat depressed patients are 1)the patients don't respond to
      antidepressant is about 40% of which, and 2) The time lag is existed until the patients
      respond to antidepressant and show the treatment effects.

      If it is predicted the response of antidepressant in advance, it would be overcome such
      problems. Drug response generally is known to be related to the individual genetic
      information and the environmental factors. We are going to investigation about antidepressant
      response using these approaches.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all pharmacogenetic and biological marker variables cause drug response</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all clinical cause drug response</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Depression</condition>
  <condition>Antidepressant Drug Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>SSRI treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-SSRI treated group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI treated group</intervention_name>
    <description>Antidepressant administration of SSRI class for 6 weeks under therapeutic dose</description>
    <arm_group_label>SSRI treated group</arm_group_label>
    <other_name>Other Names:</other_name>
    <other_name>fluoxetine_Prozac</other_name>
    <other_name>paroxetine_Paxil, Seroxat</other_name>
    <other_name>sertraline_Zoloft</other_name>
    <other_name>citalopram_Celexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-SSRI treated group</intervention_name>
    <description>Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose</description>
    <arm_group_label>non-SSRI treated group</arm_group_label>
    <other_name>venlafaxine_Effexor</other_name>
    <other_name>nortriptyline_Aventyl, Pamelor, Noritren</other_name>
    <other_name>mirtazapine_Avanza, Zispin, Remeron</other_name>
    <other_name>bupropion_amfebutamone, Wellbutrin, Zyban</other_name>
    <other_name>duloxetine_Cymbalta, Yentreve</other_name>
    <other_name>trazodone_Desyrel, Beneficat, Deprax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 25 &lt; age &lt;85

          2. major depressed patients satisfied with the diagnosis criteria depression of DSM-IV

          3. interview with one more patient's family member for objective diagnosis and final
             diagnosis decision by agreements of two more psychiatric physicians

        Exclusion Criteria:

          1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4
             weeks

          2. potential study participants for pregnancy, significant medical conditions, abnormal
             laboratory baseline values, unstable psychiatric features(eg.suicidal), history of
             alcohol of drug dependence, seizures, head trauma with loss of consciousness,
             neurological illness, or concomitant Axis I psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doh Kwan Kim, M.D.,Ph.D</last_name>
    <phone>82-2-3410-0946</phone>
    <email>jungshil.back@sbri.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shinn-Won Lim, phD</last_name>
    <phone>82-2-3410-3759</phone>
    <email>shinwon.lim@sbri.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DohKwan Kim</last_name>
    </contact>
    <investigator>
      <last_name>Doh Kwan Kim, ph.D, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>pharmacogenomics</keyword>
  <keyword>antidepressant response</keyword>
  <keyword>biological markers</keyword>
  <keyword>clinical variables</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Trazodone</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

